BLOOMFIELD, Conn., Jan. 11, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2023 financial results on Friday, February 2, 2024, and will host a conference call the same day. Fourth quarter 2023 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows: Live Call(888) 566-1889 (Domestic)(773) 799-3989 (International)Pa ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Cigna (CI) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Cigna is a member of the Medical sector. This group includes 1077 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, m ...

Summary of Cigna Group's J.P. Morgan 42nd Annual Healthcare Conference Company Overview - **Company**: Cigna Group (NYSE: CI) - **Participants**: - David Cordani - President, Chief Executive Officer & Chair - Eric Palmer - Chief Executive Officer & President, Evernorth - **Date**: January 9, 2024 Key Points 1. Strong Performance in 2023 - Cigna reported a strong performance in 2023, continuing a track record of organic growth across various operating platforms, including PBM, commercial business, international benefits, and government benefits [3][4][8] 2. EPS Guidance for 2024 - The company reiterated its EPS outlook for 2024 at least $28, which is above the high end of its growth algorithm of 10% to 13% EPS growth over time [5][8] 3. Capital-Light Business Model - Cigna operates a capital-light, service-oriented portfolio, allowing for quick conversion of operating cash flow to deployable cash flow, providing strategic advantages in a fluid business environment [6][8] 4. Innovations in Pharmacy and Healthcare - Cigna is focusing on pharmacy innovations, particularly in pharmacological advancements like GLP-1s, and aims to optimize clinical protocols for better value for patients and financiers [7][8] 5. Government Benefits Business - Cigna is committed to expanding its capabilities in the government services portfolio, including Medicare and Medicaid, and sees growth potential in this area [14][15] 6. Evernorth's Growth and Strategy - Evernorth is positioned to reduce fragmentation in healthcare delivery and improve health outcomes through partnerships, such as with VillageMD, focusing on risk-bearing and performance-based models [18][19][21] 7. Market Trends and Client Needs - There is a trend of point solution fatigue among employers, leading to a demand for more integrated healthcare solutions and precision in care delivery [40][70] 8. Retention and Growth in PBM - Cigna's PBM business is experiencing strong retention and growth, with innovations in product offerings and a focus on client satisfaction [25][26][27] 9. Legislative Environment for PBMs - The PBM industry is under scrutiny, with potential legislative changes expected. Cigna is proactively engaging with officials to ensure transparency and value delivery [62][64][66] 10. Biosimilars and Market Adoption - Cigna anticipates increased adoption of biosimilars, particularly for high-cost medications like HUMIRA, which is expected to improve affordability for clients [58][60][61] 11. Commercial Business Outlook - Cigna's commercial business is expected to grow, particularly in the Select segment, despite anticipated softening in the employment landscape [67][70][71] Additional Insights - Cigna emphasizes the importance of aligning incentives in value-based care arrangements, which can involve shared risk with manufacturers or providers [46][48] - The company is adapting to market changes, including the potential resurgence of mail-order pharmacy services due to evolving consumer preferences [54][57] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Cigna's robust performance, innovative approaches, and proactive engagement in the healthcare landscape.

The Cigna Group (NYSE:CI) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 10:30 AM ET Company Participants David Cordani - President, Chief Executive Officer & Chair Eric Palmer - Chief Executive Officer & President, Evernorth Conference Call Participants Lisa Gill - JPMorgan Lisa Gill Good Morning. My name is Lisa Gill, and I'm Head of Healthcare Services for JPMorgan. It is with great pleasure this morning that we have with us Cigna Health. With us this morning, we have CEO, David Cordani; a ...

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing. A 70% “beat rate” among the S&P 500 is typical. And an earnings beat may be a net loss that was lower than expected. It is as if companies in their guidance and analysts working for brokerage firms underestimate to set up the beats.The U.S. earnings season will begin on Friday when the largest U.S. banks report their f ...

The Cigna Group (CI) is reportedly in advanced talks to divest its Medicare Advantage business. Per a Wall Street Journal report, Health Care Service Corporation is expected to acquire the business from Cigna in a deal that can be valued at $3-$4 billion. Shares of CI fell 2.1% yesterday.The potential acquirer, Health Care Service Corporation, is a Blue Cross Blue Shield licensee in five states, including Illinois and Texas. An announcement regarding the deal is expected to be made within the coming days. L ...

Cigna Group (NYSE: CI) is now in advanced talks to sell its Medicare Advantage unit to Healthcare Services Group Inc (NASDAQ: HCSG). Its shares are down more than 1.0% at writing.Cigna-HCSG deal could be worth up to $4.0 billionCopy link to sectionAnonymous sources told the Wall Street Journal on Wednesday that the two companies are in exclusive negotiations which could lead to a $3.0 billion to $4.0 billion deal. Such an agreement, they added, will likely be announced in the coming days provided that discu ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Cigna (CI) . This company, which is in the Zacks Medical - HMOs industry, shows potential for another earnings beat.When looking at the last two reports, this health insurer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 2.08%, on average, in the last two quarters.For the las ...

Dilok Klaisataporn Quality Stocks The SPDR S&P 500 ETF Trust (SPY) posted a 4.57% return in December, ending the year on a very strong note. Vanguard's Dividend Appreciation Index Fund ETF Shares (VIG) locked in a slightly lower gain of 4.13% last month. My watchlist outperformed both, posting a very strong gain of 9.52%. The final 2023 returns are 20.89% for my watchlist, 14.50% for VIG, and 26.18% for SPY. While SPY beat my watchlist this year, since inception, the watchlist remains dominant, outperfo ...

Cigna Group (NYSE:CI) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Ralph Giacobbe - SVP & Head, IR David Cordani - President, CEO & Chair Brian Evanko - EVP & CFO Eric Palmer - CEO, President & Director Conference Call Participants Lisa Gill - JPMorgan Chase & Co. Justin Lake - Wolfe Research Kevin Fischbeck - Bank of America Merrill Lynch David Windley - Jefferies Scott Fidel - Stephens Inc. Stephen Baxter - Wells Fargo Securities Joshua Raskin - Nephron Research Gary T ...